Whilst prescribing of these drugs was low in our dataset (5% of T2D receiving GLP-1 or SGLT-2), increases in their use have the potential to further reduce the morbidity and mortality of cardiovascular disease in T2D, while making infections more prominent as a cause of death. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.